Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2

MeSH terms

• Alleles
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use*
• Biopsy
• Bone Marrow
• Gene Frequency
• Genotype
• Humans
• Janus Kinase 2 / antagonists & inhibitors*
• Janus Kinase 2 / genetics*
• Leukemia, Myelomonocytic, Chronic / diagnosis
• Leukemia, Myelomonocytic, Chronic / drug therapy*
• Leukemia, Myelomonocytic, Chronic / genetics*
• Male
• Middle Aged
• Molecular Targeted Therapy / adverse effects
• Mutation
• Nitriles
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / therapeutic use*
• Pyrazoles / administration & dosage
• Pyrazoles / adverse effects
• Pyrazoles / therapeutic use*
• Pyrimidines
• Treatment Outcome